BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…
Biotechnology
US, San Diego [HQ]
Risk Factors
By Management
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.